IN2012DE00661A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00661A
IN2012DE00661A IN661DE2012A IN2012DE00661A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A IN 661DE2012 A IN661DE2012 A IN 661DE2012A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A
Authority
IN
India
Prior art keywords
substituted
hetero
aminoquinoline
aryl
formula
Prior art date
Application number
Inventor
Singh Rawat Diwan
Manohar Sunny
Chinna Rajesh Ummadisetty
Original Assignee
Univ Delhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delhi filed Critical Univ Delhi
Priority to US14/382,727 priority Critical patent/US9567316B2/en
Priority to IN661DE2012 priority patent/IN2012DE00661A/en
Priority to PT137586780T priority patent/PT2822936T/en
Priority to ES13758678T priority patent/ES2899730T3/en
Priority to PCT/US2013/028329 priority patent/WO2013134047A2/en
Priority to EP13758678.0A priority patent/EP2822936B1/en
Priority to EP21194376.6A priority patent/EP3971178A1/en
Publication of IN2012DE00661A publication Critical patent/IN2012DE00661A/en
Priority to US15/404,964 priority patent/US11026943B2/en
Priority to US17/240,886 priority patent/US20220008418A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to aminoquinoline based hybrids and uses thereof, comprising of 4-aminoquinoline, 8-aminoquinoline, mefloquine, amidoquine& all combinations thereof, with general formula (I) as herein described: (Formula Removed) Formula (I) Wherein R is independently absent or selected from the group of substituted or un-substituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl; halogen, substituted or unsubstitutedalkoxy, nitro, cyno, carbonyl, hydroxyl, phenoxy, thio, and substituted or unsubstituted aryl or hetero-aryl; R1-R7 are independently absent or selected from the group of substituted or un-substituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl; halogen, substituted or unsubstitutedalkoxy, nitro, cyno, carbonyl, hydroxyl, phenoxy, thio, and substituted or unsubstituted aryl or hetero-aryl; the six membered ring with X, Y, Z be all CH or combination of CH, X/Y/Z or any other combination where X, Y, Z being N, O, S or any other biologically relevant atoms or fused heteroaromatic system such as pyrimidine, pyrazine, triazine and all other heteroaromatics with various substitution patterns and n = 0 -16, the (CH2)n being a linker or spacer, and it can be aromatic, hetero¬aromatic or cyclic systems.
IN661DE2012 2012-03-07 2013-02-28 IN2012DE00661A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US14/382,727 US9567316B2 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
IN661DE2012 IN2012DE00661A (en) 2012-03-07 2013-02-28
PT137586780T PT2822936T (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
ES13758678T ES2899730T3 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and their uses
PCT/US2013/028329 WO2013134047A2 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
EP13758678.0A EP2822936B1 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
EP21194376.6A EP3971178A1 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
US15/404,964 US11026943B2 (en) 2012-03-07 2017-01-12 Aminoquinoline derivatives and uses thereof
US17/240,886 US20220008418A1 (en) 2012-03-07 2021-04-26 Aminoquinoline Derivatives and Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN661DE2012 IN2012DE00661A (en) 2012-03-07 2013-02-28

Publications (1)

Publication Number Publication Date
IN2012DE00661A true IN2012DE00661A (en) 2015-08-21

Family

ID=49117483

Family Applications (1)

Application Number Title Priority Date Filing Date
IN661DE2012 IN2012DE00661A (en) 2012-03-07 2013-02-28

Country Status (6)

Country Link
US (3) US9567316B2 (en)
EP (2) EP2822936B1 (en)
ES (1) ES2899730T3 (en)
IN (1) IN2012DE00661A (en)
PT (1) PT2822936T (en)
WO (1) WO2013134047A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188077A1 (en) * 2014-06-06 2015-12-10 Board Of Trustees Of Michigan State University Nurr1 as a genetic target for treating levodopa-induced dyskinesias in parkinson's disease
CN104070943B (en) * 2014-07-23 2017-10-17 万通智控科技股份有限公司 A kind of self-programming tire pressure monitoring device and implementation method
WO2016111957A1 (en) * 2015-01-06 2016-07-14 Albert Einstein College Of Medicine, Inc. Chloroquinoline triazole compounds, composition and uses
US10004727B2 (en) 2015-02-16 2018-06-26 Postech Academy-Industry Foundation Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient
US10329258B2 (en) 2015-04-30 2019-06-25 University Of Washington CGAS in systemic lupus erythematosus (SLE)
WO2016205371A1 (en) * 2015-06-15 2016-12-22 Mayo Foundation For Medical Education And Research Using autologous mesenchymal stem cells to treat multiple system atrophy
CN105301126B (en) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 Method for analyzing topiroxostat-related substances
KR101934328B1 (en) 2016-08-12 2019-01-02 주식회사 노브메타파마 Pharmaceutical composition for preventing or treating diabetes mellitus containing amodiaquine and antidiabetic drug
US11612583B2 (en) 2018-06-21 2023-03-28 Nevada Research & Innovation Corporation Disease modifying methods for treating neurodegenerative diseases using nootropic agents
CN109620971A (en) * 2018-12-14 2019-04-16 昆明医科大学第附属医院 A method of screening prevention and treatment anti-parkinson drug
JP2022544700A (en) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド Molecules that Bind TDP-43 for the Treatment of Amyotrophic Lateral Sclerosis and Related Disorders
US20230022696A1 (en) * 2019-10-29 2023-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of autophagy and histone deactylases and uses thereof
KR20230035588A (en) * 2020-07-07 2023-03-14 더 맥클린 하스피털 코퍼레이션 Compounds and methods for treating neurodegenerative diseases
EP4294811A2 (en) * 2021-02-20 2023-12-27 Biohaven Therapeutics Ltd. Small molecules that bind to tdp-43 for the treatment of als and related disorders
WO2023159062A2 (en) * 2022-02-15 2023-08-24 University Of Central Florida Research Foundation, Inc. Anabolic drugs stimulating type ii collagen production from chondrocytes or their progenitors
WO2024049718A2 (en) * 2022-08-31 2024-03-07 Immunocure Inc. Quinoline piperazine derivatives, pharmaceutical composition and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR82308A (en) 1961-12-29 1900-01-01
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4487761A (en) 1982-04-05 1984-12-11 Merck & Co., Inc. Dopamine β-hydroxylase inhibitors
US4992459A (en) 1983-04-12 1991-02-12 Smithkline Beecham Corporation Dopamine-β-hydroxylase inhibitors
US4906668A (en) 1984-08-23 1990-03-06 Georgia Tech Research Corporation Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
US4634711A (en) 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
US4719223A (en) 1985-10-31 1988-01-12 Smithkline Beckman Corporation Imidazolethiol dopamine-beta-hydroxylase inhibitors
US4743613A (en) 1986-04-08 1988-05-10 Smithkline Beckman Corporation Ester prodrugs of dopamine-β-hydroxylase, inhibitors, composition containing them, and method of using them to inhibit dopamine-β-hydroxylase activity
US5189052A (en) 1986-05-06 1993-02-23 Merrell Dow Pharmaceuticals Inc. Thione dopamine beta hydroxylase inhibitors
US4810800A (en) 1986-05-06 1989-03-07 Merrell Dow Pharmaceuticals Inc. Novel imidazole dopamine beta hydroxylase inhibitors
US4761415A (en) 1986-08-28 1988-08-02 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4749717A (en) 1987-01-08 1988-06-07 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
US4859779A (en) 1987-03-24 1989-08-22 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4762850A (en) 1987-03-24 1988-08-09 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
US4835154A (en) 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US4798843A (en) 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
US4839371A (en) 1987-09-17 1989-06-13 Smithkline Beckman Corporation 3-aralkyl-2-mercaptoyridines as dopamine-β-hydroxylase inhibitors
US4882348A (en) 1987-12-29 1989-11-21 Smithkline Beckman Corporation 2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitors
US4935438A (en) 1987-12-29 1990-06-19 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4876266A (en) 1987-12-31 1989-10-24 Smithkline Beckman Corporation 1-aralkyl-2-mercaptoimidazolines as DBH inhibitors
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4935449A (en) 1988-08-04 1990-06-19 Merrell Dow Pharmaceuticals Inc. N-2,3-butadienyl tri- and tetraaminoalkane derivatives
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5100912A (en) 1990-05-14 1992-03-31 Syntex (U.S.A.) Inc. Bis(benzylpyrrolidine) derivatives as dopamine agonists
US5108899A (en) 1989-10-31 1992-04-28 Exoxemis, Inc. Chemiluminescence assay of in vivo inflammation
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
DE69432217T2 (en) 1993-04-06 2004-04-08 Abbott Laboratories, Abbott Park TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS
US5550139A (en) 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
EP0934249B1 (en) 1996-10-18 2002-03-27 Wisconsin Alumni Research Foundation Conformationally restricted polyamines and their use as antineoplastic agents
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
MXPA01009871A (en) 1999-04-01 2002-04-24 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors.
JP2002543163A (en) 1999-04-30 2002-12-17 スリル バイオメディカル コーポレイション Conjugates as treatments for cancer and prostate disease
CA2371625C (en) 1999-04-30 2012-04-17 Slil Biomedical Corporation Polyamines and their use in therapy
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
CA2417064A1 (en) 2000-08-02 2002-02-07 Slil Biomedical Corporation Cyclic polyamine compounds for cancer therapy
WO2003012040A2 (en) 2001-07-27 2003-02-13 Baylor College Of Medecine Mutant nurr1 gene in parkinson's disease
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003070244A1 (en) * 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
EP1534681A1 (en) * 2002-06-27 2005-06-01 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
US7899888B2 (en) * 2002-06-28 2011-03-01 Oracle America, Inc. Runtime versioning of information processing systems
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1635763B1 (en) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
CN101466380A (en) * 2006-02-16 2009-06-24 麦克莱恩医院 Methods and compositions for the treatment of parkinson's disease
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
US20110045100A1 (en) * 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof
US8628962B2 (en) 2008-11-18 2014-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Differentiation of stem cells into dopaminergic cells
EP2379505A4 (en) * 2008-12-05 2012-10-17 Designmedix Inc Modified chloroquines with single ring moiety or fused ring moiety

Also Published As

Publication number Publication date
ES2899730T3 (en) 2022-03-14
EP2822936A4 (en) 2016-04-20
WO2013134047A2 (en) 2013-09-12
EP3971178A1 (en) 2022-03-23
WO2013134047A3 (en) 2013-10-31
US11026943B2 (en) 2021-06-08
US20150023930A1 (en) 2015-01-22
EP2822936B1 (en) 2021-09-08
US9567316B2 (en) 2017-02-14
US20170209441A1 (en) 2017-07-27
US20220008418A1 (en) 2022-01-13
EP2822936A2 (en) 2015-01-14
PT2822936T (en) 2021-12-02

Similar Documents

Publication Publication Date Title
IN2012DE00661A (en)
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
MA34389B1 (en) NEW AMINOPYRAZOLOQUINAZOLINES
EP3670496A3 (en) Acc2 inhibitors
MX2016005993A (en) Biscationic and triscationic amphiles as antimicrobial agents.
SG195289A1 (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX369324B (en) 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors.
PH12015500347A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TN2009000342A1 (en) Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors
MD4575C1 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
NZ705313A (en) Novel 4,6-disubstituted aminopyrimidine derivatives
SA515361086B1 (en) Novel compounds and compositions for inhibition of FASN
CR20150268A (en) NEW COMPOUNDS
IN2014CN03976A (en)
MX347241B (en) Aminopyrimidine derivatives for use as modulators of kinase activity.
MX2014014531A (en) Aminoquinazoline and pyridopyrimidine derivatives.
MX346746B (en) Indeno- fused ring compounds having photochromic properties.
BR112012029647A2 (en) new pyrimidine derivatives
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
PH12016500480A1 (en) Antibacterial 2h-indazole derivatives
MX368882B (en) Process for the preparation of triazines.
MX2015008543A (en) Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopro pyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline.
EA201692305A1 (en) ANTIBACTERIAL HINAZOLIN-4 (3H) -ONE DERIVATIVES
MX2016000621A (en) Improved process for preparing chlorinated biphenylanilides and biphenylanilines.
MX353190B (en) Isoquinoline and naphthyridine derivatives.